The Department of Veterans Affairs is launching a nationwide clinical trial to determine whether semaglutide can help treat alcohol use disorder, a condition officially diagnosed in more than 400,000 veterans nationwide, according to department data. VA researchers are studying the GLP-1 receptor agonist—marketed as Ozempic for Type 2 diabetes and Wegovy for chronic weight management—to … Read more
Popular weight loss drugs like Ozempic and Wegovy could deliver measurable economic benefits by significantly reducing employee sick leave, according to an economic study published this month by the National Bureau of Economic Research. The research found that GLP-1 medications resulted in workers taking 17 percent less long-term sick leave, translating to substantial financial savings … Read more
The rise of GLP-1 receptor agonists like Ozempic marks a transition toward a “body economy” where medical interventions, social media filters, and aesthetic procedures are increasingly viewed as mandatory for personal and professional success. According to the CCCB contemporary arts center exhibition The Cult of Beauty, this shift reinforces historical standards of perfection while rebranding … Read more
The prevalence of GLP-1 drugs for weight loss among U.S. adults has reached a record high, with 11% of the population currently using medications like Ozempic and Wegovy, according to a Gallup survey of 5,065 adults conducted between May 28 and June 5. This surge correlates with a decline in the national obesity rate, which … Read more
GLP-1 medications like Ozempic and Wegovy may increase resting heart rate and decrease heart rate variability, according to a study by WHOOP published in the American Journal of Physiology, Heart and Circulatory Physiology. While 90% of users in the study lost at least 5% of their body weight within 12 weeks, the data reveals a … Read more
Driven by the rising accessibility of GLP-1 weight-loss medications, a growing number of individuals are turning to unregulated, DIY fat-dissolving injections to contour their bodies at home. While users claim these black-market substances offer a low-cost alternative to surgical liposuction, medical professionals warn that self-administering these chemical agents poses severe health risks, including permanent skin … Read more
Unemployed women who begin taking GLP-1 weight-loss medications like Ozempic or Wegovy experience a 27% increase in their employment rate within 18 months, according to a working paper from the National Bureau of Economic Research (NBER). Harvard economist Rebecca Diamond, who analyzed survey data from over 10,000 adults, found that these gains appear tied to … Read more
Travelers using weight loss medications such as Ozempic, Wegovy, or Mounjaro must disclose their use to insurance providers to ensure coverage remains valid. The Association of British Insurers (ABI) warns that failing to declare prescribed medications or the underlying health conditions they treat can lead to invalidated policies and rejected claims, potentially leaving holidaymakers responsible … Read more
Pharmaceutical companies are racing to develop drugs that prevent muscle loss during weight reduction, addressing a critical side effect of GLP-1 medications like Ozempic and Zepbound. While current weight-loss drugs often cause patients to lose significant lean mass alongside fat, new candidates—including bimagrumab and Cambrian Biotech’s ATX-304—aim to prioritize metabolic health and muscle preservation, according … Read more
GLP-1 receptor agonists, such as semaglutide, appear to weaken the link between impulsive personality traits and violent behavior in current users, according to a study published in the journal Criminology. Researchers at Rutgers University found that the association between impulsivity and violence was 62% weaker in people currently taking these medications compared to those who … Read more